BIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

03/16

Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:

• Approval of the consolidated annual results for the financial year ended 31 December 2025. • Review and potential recommendation of a final dividend for shareholders.

The meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.

Further details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1132847716"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132847716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132847716?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132847716","market":"us","top_or_hot":-1,"title":"BIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:</p>\n<p>• Approval of the consolidated annual results for the financial year ended 31 December 2025.  \n• Review and potential recommendation of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.</p>\n<p>Further details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-16 16:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:</p>\n<p>• Approval of the consolidated annual results for the financial year ended 31 December 2025.  \n• Review and potential recommendation of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.</p>\n<p>Further details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1132847716","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132847716","pubTimestamp":1773650473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes: • Approval of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"BIOHEART-B(02185)定于2026年3月26日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:\n• Approval of the consolidated annual results for the financial year ended 31 December 2025.  \n• Review and potential recommendation of a final dividend for shareholders.\nThe meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.\nFurther details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}